Predictive Oncology has a Cash Ratio of 1.15. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Predictive Oncology's Cash Ratio or its related term are showing as below:
POAI'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 1.23 Max: 13.99
Current: 1.15
During the past 13 years, Predictive Oncology's highest Cash Ratio was 13.99. The lowest was 0.01. And the median was 1.23.
POAI's Cash Ratio is ranked worse than 51.23% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 1.21
vs POAI: 1.15
Predictive Oncology Cash Ratio Historical Data
The historical data trend for Predictive Oncology's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Predictive Oncology's Cash Ratio
For the Medical Instruments & Supplies subindustry, Predictive Oncology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predictive Oncology's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Predictive Oncology's Cash Ratio falls into.
Predictive Oncology Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Predictive Oncology's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Predictive Oncology (NAS:POAI) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Predictive Oncology Cash Ratio Related Terms
Thank you for viewing the detailed overview of Predictive Oncology's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Predictive Oncology (Predictive Oncology) Business Description
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
POAI has been successfully added to your 